Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2011 by Vanderbilt-Ingram Cancer Center.
Recruitment status was:  Active, not recruiting
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
Vanderbilt-Ingram Cancer Center
ClinicalTrials.gov Identifier:
NCT00550537
First received: October 26, 2007
Last updated: July 20, 2011
Last verified: July 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)